Collagen XXIII expression is associated with prostate cancer recurrence and distant metastases

Jacqueline Banyard, Lere Bao, Matthias D. Hofer, David Zurakowski, Kristin A. Spivey, Adam S. Feldman, Lloyd M. Hutchinson, Rainer Kuefer, Mark A. Rubin, Bruce R. Zetter*

*Corresponding author for this work

Research output: Contribution to journalArticle

25 Scopus citations

Abstract

Purpose: We had previously identified a new transmembrane collagen, type XXIII, in metastatic rat prostate carcinoma cells. The purpose of this study was to determine the expression of collagen XXIII in human prostate cancer and investigate its relationship with disease progression. Experimental Design: We investigated collagen XXIII expression in prostate cancer tissue and did a retrospective analysis of association with prostate-specific antigen (PSA) - defined disease recurrence. The presence of collagen XXIII in prostate cancer patient urine was also assessed before and after prostatectomy. Results: Collagen XXIII protein was detected at very low levels in benign prostate tissue and was significantly increased in prostate cancer. Distant metastases exhibited significantly higher collagen XXIII levels compared with either localized prostate cancer or regional (lymph node) metastases. Patients with high collagen XXIII levels had a 2.8-fold higher risk of PSA failure with median time to failure of 8.1 months, compared with low collagen XXIII patients with a median time to failure of 5 years. Multivariate Cox regression showed that the presence of collagen XXIII was significantly associated with time to PSA recurrence, independent of other clinical variables. Collagen XXIII was also detected in prostate cancer patient urine, with reduced levels after prostatectomy, indicating potential as a noninvasive fluid biomarker. Conclusions: We present the first report demonstrating increased collagen XXIII expression in prostate cancer tissue. We show that collagen XXIII level is a significant independent predictor of PSA-defined disease recurrence, suggesting a potential role as a molecular biomarker of prostate cancer progression and metastasis.

Original languageEnglish (US)
Pages (from-to)2634-2642
Number of pages9
JournalClinical Cancer Research
Volume13
Issue number9
DOIs
StatePublished - May 1 2007

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Collagen XXIII expression is associated with prostate cancer recurrence and distant metastases'. Together they form a unique fingerprint.

  • Cite this

    Banyard, J., Bao, L., Hofer, M. D., Zurakowski, D., Spivey, K. A., Feldman, A. S., Hutchinson, L. M., Kuefer, R., Rubin, M. A., & Zetter, B. R. (2007). Collagen XXIII expression is associated with prostate cancer recurrence and distant metastases. Clinical Cancer Research, 13(9), 2634-2642. https://doi.org/10.1158/1078-0432.CCR-06-2163